The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data

被引：0

作者：

Hans Rollema

Raymond S. Hurst

机构：

[1] Rollema Biomedical Consulting,

[2] Hurst Neuropharmacology Consulting,undefined

[3] Concert Pharmaceuticals,undefined

[4] Inc.,undefined

来源：

Psychopharmacology | 2018年 / 235卷

关键词：

α4β2 nAChR agonists; α6β2* nAChR agonists; nAChR activation and desensitization; Agonist-antagonist activities; Smoking cessation; NRT; Varenicline; Cytisine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2479 / 2505

页数：26

共 14 条

[1] The contribution of agonist and antagonist activities of α4β2*nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data
Rollema, Hans
Hurst, Raymond S.
PSYCHOPHARMACOLOGY, 2018, 235 (09) : 2479 - 2505
[2] Discovery and pharmacology of varenicline: An a4b2 nAChR partial agonist for smoking cessation
Rollema, H.
Coe, J. W.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S55 - S55
[3] Smoking cessation efficacy and safety of varenicline, an α4β2 nicotinic receptor partial agonist
Tonstad, Serena
JOURNAL OF CARDIOVASCULAR NURSING, 2006, 21 (06) : 433 - 436
[4] CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation
Sala, Mariaelvina
Braida, Daniela
Pucci, Luca
Manfredi, Irene
Marks, Michael J.
Wageman, Charles R.
Grady, Sharon R.
Loi, Barbara
Fucile, Sergio
Fasoli, Francesca
Zoli, Michele
Tasso, Bruno
Sparatore, Fabio
Clementi, Francesco
Gotti, Cecilia
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 168 (04) : 835 - 849
[5] Efficacy and safety of varenicline, an α4β2 acetylcholine nicotinic receptor partial agonist, for smoking cessation in Japanese smokers
Nakamura, Masakazu
Fujimoto, Yoko
Maruyama, Nami
Ishibashi, Taro
Reeves, Karen
CIRCULATION, 2006, 114 (18) : 856 - 856
[6] The efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation in Taiwanese and Korean smokers
Kim, Dac-Hyun
Tsai, Shih-Tzu
Cho, Hong-Jun
Chang, Wen-Dau
Kim, Cheol-Hwan
Cheng, Huey-Shinn
Cho, BeLong
Guo, Fei-Rarl
Paek, Yu-Jin
Hsueh, Kuang-Chieh
Billing, Clare B., Jr.
Williams, Kathryn E.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 122 : 82 - 82
[7] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
Jorenby, Douglas E.
Hays, J. Taylor
Rigotti, Nancy A.
Azoulay, Salomon
Watsky, Eric J.
Williams, Kathryn E.
Billing, Clare B.
Gong, Jason
Reeves, Karen R.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 56 - 63
[8] Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism:: Analysis of pooled data from two clinical trials
David, Sean P.
Strong, David R.
Munafo, Marcus R.
Brown, Richard A.
Lloyd-Richardson, Elizabeth E.
Wileyto, Paul E.
Evins, Eden A.
Shields, Peter G.
Lerman, Caryn
Niaura, Raymond
NICOTINE & TOBACCO RESEARCH, 2007, 9 (12) : 1251 - 1257
[9] The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized With Acute Coronary Syndrome: A Randomized Controlled Trial
Eisenberg, Mark J.
Windle, Sarah B.
Roy, Nathalie
Old, Wayne
Grondin, Franois
Bata, Iqbal
Iskander, Ayman
lauzon, Claude
Srivastava, Nalin
Clarke, Adam
Cassavar, Daniel
Dion, Danielle
Haught, Herbert
Mehta, Shamir
Baril, Jean-Francois
Lambert, Charles
Madan, Mina
Abramson, Beth L.
Dehghani, Payam
CIRCULATION, 2015, 132 (23) : 2269 - 2270
[10] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation:: A randomized controlled trial (vol 296, pg 56, 2006)
Jorenby, D. E.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (11): : 1355 - 1355

← 1 2 →